In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

ACROBiosystems is breaking the chain of chronic suffering and safeguarding intestinal health. Learn how in this article.

NANJING, China, July 25, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" ...

For decades, the narrative around Parkinson’s disease treatment has focused primarily on dopamine replacement. The loss of ...

Creatine supplementation may improve cognitive performance and mood, offering insights into its role in muscle-brain ...

Genetic Leap, a clinical stage, AI-native biotech pioneering RNA genetic therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) ...

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of ...

MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes ...

The ABTECT clinical program included the randomized, double-blind, placebo-controlled phase 3 ABTECT-1 and ABTECT-2 trials.

The FDA clears GL-IL2-138, a groundbreaking oral drug modulating natural IL-2, set to revolutionize treatment in oncology.

From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction.

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ-151 cream 0.3%, MP1032, Risankizumab, Certolizumab Pegol , and others.